Current reports
Current report No. 23/2023 – Correction of the Periodical Report
2023-10-11
Current report No. 22/2023 – Signing of an agreement for the implementation and co-funding of Celon Pharma S.A.’s project on clinical development of the innovative CPL110 inhibitor in FGFR-dependent solid tumors
2023-10-11
Current report No. 21/2023 – Receipt of a notification regarding a change in the total number of votes in the Company
2023-10-11
Current report No. 20/2023 – Change in the composition of the Management Board of Celon Pharma S.A.
2023-10-11
Current report No. 19/2023 – Appointment of existing members of the Company’s Supervisory Board for another term
2023-10-11
Current report No. 17/2023 K – Resolutions adopted by the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2023 – correction
2023-07-03
Current report No. 18/2023 – List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of Celon Pharma S.A. held on June 22, 2023
2023-07-03
Current report No. 17/2023 – Resolutions adopted by the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2023
2023-07-03
Current report No. 16/2023 – Resolution of the Ordinary General Meeting of the Company on coverage of loss and payment of the dividend for the financial year 2022
2023-07-03
Current report No. 15/2023 – Statement of the Central Securities Depository of Poland (KDPW) on assimilation of 21,500 C-series shares with the Company’s shares currently traded in the stock exchange
2023-07-03
Current report 14/2023 – Admission and introduction of 21,500 ordinary C-series bearer shares of the Company to stock exchange trading
2023-07-03
Current report No. 13/2023 – Celon Pharma S.A.’s project on clinical development of the innovative CPL110 inhibitor in FGFR-dependant solid tumors will receive co-funding
2023-06-20
Current report No. 12/2023 – Allocation of 21,500 C-series shares under a conditional share capital increase
2023-06-20
Current report No. 11/2023 – Notification on the acquisition of C-series shares of Celon Pharma S.A. by a person discharging managerial responsibilities
2023-06-20
Current report No. 10/2023 – Notice on the convening of the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2023 with draft resolutions
2023-06-20
Current report No. 9/2023 – The Management Board’s and the Supervisory Board’s recommendation on the coverage of loss for the year 2022 and payment of the dividend
2023-06-20
Current report No. 8/2023 – Notification about a transaction on subscription warrants of Celon Pharma S.A.
2023-06-20
Current report No. 7/2023 – Successful tender for the supply of Company’s products to the Persian Gulf countries
2023-06-20
Current report No. 6/2023 – Allocation of A-series subscription warrants to eligible persons under the Incentive Program for Members of the Management Board of the Company for 2022
2023-06-20
Current report No. 5/2023 – Change of the date of publication of the annual report for 2022
2023-04-21
Current report No. 4/2023 – Cancellation of the managing person
2023-04-13
Current report No. 3/2023 – Information regarding the Company’s meeting with the Food and Drug Administration (FDA) under the End of Phase II (EOP2) meeting procedure for Celon’s esketamine DPI (Falkieri) project
2023-03-24
Current report No. 2/2023 – Receipt of a notification regarding a change in the total number of votes in the Company
2023-03-24
Current report No. 1/2023 – Dates for submitting periodic reports in 2023
2023-03-24
Current report No. 28/2022 – Signing of an agreement on implementing and co-funding Celon Pharma S.A.’s project on a new therapeutic target for the FGF1 protein analogue
2023-03-24
Current report No. 27/2022 – Signing of an agreement on implementing and co-funding Celon Pharma S.A.’s project on improving drug safety by implementing innovative forms of orally administered medicinal products to Celon Pharma S.A.’s in-house production
2023-03-24